Literature DB >> 7922463

A comparison of the pathology of primary and secondary progressive multiple sclerosis.

T Revesz1, D Kidd, A J Thompson, R O Barnard, W I McDonald.   

Abstract

The dynamics of primary progressive multiple sclerosis differ from those of the more common secondary progressive form. The observation by MRI that the frequency of enhancement with gadolinium-DTPA, a marker for blood-brain barrier dysfunction, is significantly less in the primary progressive form, has led to the hypothesis that inflammation is less intense in this group. To test this, we have studied postmortem material from nine cases judged from a retrospective analysis of case notes to show clear clinical evidence of either primary progressive or secondary progressive disease. Five hundred and seventy-eight lesions were analysed. There was significantly more inflammation in secondary progressive multiple sclerosis (as judged by the frequency of perivascular cuffing and cellularity of the parenchyma) than in primary progressive disease. These observations have implications for therapeutic strategies in progressive multiple sclerosis.

Entities:  

Mesh:

Year:  1994        PMID: 7922463     DOI: 10.1093/brain/117.4.759

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  49 in total

1.  Interferon-gamma activated calcium influx in peripheral blood lymphocytes from patients with primary and secondary progressive multiple sclerosis.

Authors:  G Martino; E Brambilla; M Filippi; V Martinelli; B Colombo; M Rodegher; G Comi; L M Grimaldi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 2.  Prognostic factors for multiple sclerosis: the importance of natural history studies.

Authors:  George C Ebers
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

3.  Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis.

Authors:  Tineke Hooper-van Veen; Johannes Berkhof; Chris H Polman; Bernard M J Uitdehaag
Journal:  Immunogenetics       Date:  2006-04-13       Impact factor: 2.846

4.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.

Authors:  G C DeLuca; S V Ramagopalan; B M Herrera; D A Dyment; M R Lincoln; A Montpetit; M Pugliatti; M C N Barnardo; N J Risch; A D Sadovnick; M Chao; S Sotgiu; T J Hudson; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

5.  Progressive myoclonic ataxia with intrathecal immune activation in six patients.

Authors:  D Testa; E Ambrosoni; S Franceschetti; A Salmaggi; P Soliveri; F Girotti
Journal:  Neurol Sci       Date:  2007-08-10       Impact factor: 3.307

6.  Functional MR imaging correlates of neuropsychological impairment in primary-progressive multiple sclerosis.

Authors:  M A Rocca; G Riccitelli; M Rodegher; A Ceccarelli; A Falini; M Falautano; A Meani; G Comi; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

7.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

8.  Cortical plaques visualised by fluid-attenuated inversion recovery imaging in relapsing multiple sclerosis.

Authors:  M D Boggild; R Williams; N Haq; C P Hawkins
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

9.  Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses.

Authors:  M-L Sumelahti; P J Tienari; M Hakama; J Wikström
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

Review 10.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.